NASDAQ
SLXN
Last Price
US $2.50
Valuation
Financial
Performance
Financial risk - Cash flow debt coverage.
Silexion Therapeutics Ltd. cash flow to debt ratio of -2.31K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.
Financial risk - Healthy cash flow growth.
Silexion Therapeutics Ltd.'s free cash flow has decreased 28.63% from $-8.42M last year to $-10.83M, signaling decreasing performance
Financial risk - Healthy debt to equity ratio.
Silexion Therapeutics Ltd.'s debt to equity ratio is 1.50, which means that the company's assets are unhealthy financed, signaling financial risk. READ MORE: A ratio over 0.60 means the company finances its assets with debt, signaling financial risk. If ratio is negative, the company spent its own equity and risks bankruptcy
Financial risk - Healthy debt to equity ratio development.
Silexion Therapeutics Ltd.'s debt has increased relative to shareholder equity from -1.13 last year to 1.50 today, signaling weakened financials
Financial risk - Net debt/EBITDA.
Silexion Therapeutics Ltd. has negative EBITDA, making leverage ratio unreliable
Financial stability - ICR.
Silexion Therapeutics Ltd. earns at least as much interest as it pays. Interest obligations are fully covered.
Financial risk - Profit margin growth.
Silexion Therapeutics Ltd. has insufficient data to evaluate this check.
Financial stability - Short term assets vs short term liabilities.
Silexion Therapeutics Ltd.'s short-term assets of $6.64M exceed its short-term liabilities of $2.76M
Decreasing performance - ROA.
Silexion Therapeutics Ltd.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization
Decreasing performance - Absolute return on equity.
Silexion Therapeutics Ltd.'s return on equity of -516.87%, is lower than 15.00%, indicating bad performance
Decreasing performance - Earnings quality.
Silexion Therapeutics Ltd.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation
Decreasing performance - Earnings stability.
Silexion Therapeutics Ltd. had positive net income in only 0.00 out of 5 years, indicating unstable earnings
Decreasing performance - Free cash flow.
Silexion Therapeutics Ltd. has negative free cash flow, indicating the company is burning cash rather than generating it
Decreasing performance - FCF yield.
Silexion Therapeutics Ltd. has negative free cash flow, indicating cash burn
Increasing performance - Healthy earnings growth.
Silexion Therapeutics Ltd.'s yearly earnings has increased -27.56% since last year from $-16.44M to $-11.91M, signaling increasing performance
Increasing performance - Healthy revenue growth.
Silexion Therapeutics Ltd.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance
Increasing performance - ROIC.
ROIC 1.45K% (Source: FMP key-metrics). At or above the 10% threshold. Score: 2 of 2. The company is generating returns above the upper end of the typical US weighted-average cost of capital range under this definition of invested capital.
Decreasing performance - 3-year revenue CAGR.
Silexion Therapeutics Ltd. has insufficient revenue history to calculate 3-year revenue CAGR.
Increasing performance - Revenue consistency.
Silexion Therapeutics Ltd. had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance
Decreasing performance - ROE consistency.
Silexion Therapeutics Ltd. had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity
Overvalued - DCF valuation.
Silexion Therapeutics Ltd. has insufficient data to evaluate this check.
Overvalued - Earnings yield.
Silexion Therapeutics Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Overvalued - EBITDA valuation.
Silexion Therapeutics Ltd. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model
Overvalued - EV/EBITDA.
Silexion Therapeutics Ltd. has negative or missing EBITDA, making EV/EBITDA ratio unreliable
Overvalued - PEG ratio value.
Silexion Therapeutics Ltd. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails
Undervalued - P/B ratio.
Silexion Therapeutics Ltd. has a price-to-book ratio of 2.78x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Overvalued - P/S ratio.
Silexion Therapeutics Ltd. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue
Profit margin
Current Ratio
Capital Returns
-516.87%
Return on equity
ROIC: 1448.83%
Valuation History
0.05X
Price to Earnings
EV/EBITDA: 0.07X
Cash flow
Profit margin
-56.00%
(FY vs FY)
Cash flow Y/Y
-63.01%
(FY vs FY)
Fair Value
Market $2.50
—
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.